# Orexo Q3 2026 Earnings Call Highlights

> Orexo AB reports progress on FDA submission and clinical trial approvals for key products.
- Title: Orexo Q3 2026 Earnings Call Highlights · Seekingalpha
- Summary: Orexo AB reports progress on FDA submission and clinical trial approvals for key products. Orexo AB achieved FDA submission for Izipry and IND acceptance for…
- Keywords: orexo ab, q3 2026, earnings call, fd a submission, ox640, izipry, clinical trial, transformation, money, business, Orexo, 2026
- Source: Seekingalpha — https://seekingalpha.com/article/4956518-orexo-ab-publ-orxoy-q3-2026-earnings-call-transcript
- Author: SA Transcripts
- Published: 2026-10-22T16:07:35+00:00
- Read time: 1 min
- Topics: orexo ab, q3 2026, earnings call, fd a submission, ox640, izipry, clinical trial, transformation, money, business
## Q3 2026 Earnings Report
Orexo AB presented Q3 2026 earnings with CEO Nikolaj Sørensen and CFO Frederik Jarrsten.
## FDA Submission for Izipry
Orexo resubmitted Izipry to FDA on September 29 for a 6-month review ending in Q1 2027.
## OX640 Clinical Trial Progress
Orexo received IND acceptance for OX640, confirming its clinical trial program for the quarter.
## Key takeaway

Orexo AB achieved FDA submission for Izipry and IND acceptance for OX640, advancing its transformation into a platform-focused company.